Recently, Xu Yan, East Lake District People's Hospital of Wuhan City, Hubei Province, studied benazepril hydrochloride tablets and valsartan elderly patients with acute myocardial infarction in patients with cardiac function in a randomized controlled study found that benazepril hydrochloride tablets and valsalva Tan treatment of elderly AMI are lipid-lowering, patency of blood vessels, can significantly reduce the risk of death and disability of cardiovascular disease and improve the quality of life of patients, but benazepril hydrochloride effect better than valsartan. This article was published in "2016 China Pharmaceuticals".
The aim of this study was to compare the effects of benazepril hydrochloride and valsartan
on cardiac function in elderly patients with acute myocardial infarction (AMI).
The researchers divided 100 elderly patients with AMI according to the random number table into the control group and the experimental group, 50 cases each. Patients in the control group were treated with valsartan. Patients in the test group were treated with benazepril hydrochloride tablets, and the clinical efficacy was compared between the two groups.
The results showed that after treatment, the total effective rate in the experimental group was 96.67%, which was significantly higher than that in the control group (70.00%, P <0.05). Before and after treatment, the left ventricular ejection fraction (LVEF) (P <0.05). The total cholesterol (TC) of the test group was (3.12 ± 0.78) mmol / L and the level of low density lipoprotein cholesterol (LDL-C) was (1.48 ± 0.46 ) mmol / L were significantly lower than those in the control group (3.94 ± 0.79) mmol / L and (2.39 ± 0.94) mmol / L respectively (P <0.05).